Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Brolucizumab, ATC S01LA06 für die Zeit 01.09.2026 - 31.08.2028

TENDER DESCRIPTION

DAK-Gesundheit assumes that this procedure does not fall within the scope of cartel procurement law due to the absence of a selection decision and thus the non-discriminatory access possibility for all pharmaceutical companies. It will end automatically regardless upon the entry into force of the exclusive contract for the active substance Brolucizumab, ATC S01LA06, following a formal procurement procedure according to the regulations of Part 4 of the GWB with one or more contracting partners. To do justice to the variety of potential contracting partners within the framework of the approval model, each pharmaceutical company is enabled to conclude a framework agreement at any time during the contract term and under the same conditions. The necessary contract documents are available for download via the online portal www.dtvp.de/center at the link referenced under 5.1.11. Conditions for concluding or later joining the contracts that first come into effect on 01.09.2026 are the complete and timely submission of the following documents (available for download at the link under 5.1.11) to the following department at DAK-Gesundheit: 1. Offer letter 2. Acceptance of the contractual…

TENDER BRIEF

TENDER DOCUMENTS